Plain-English translation of NCT07828405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing soy isoflavones—a natural compound found in soy—as a potential way to prevent asthma in very young children who get a viral respiratory infection. Researchers believe that certain babies have a genetic variation that makes them more likely to develop asthma after a respiratory virus. The medication may help by reducing harmful inflammation and scarring in the airways during illness.
Asthma often starts in infancy after a serious respiratory virus, especially in children with certain genetic risk factors. Current treatments focus on managing asthma after it develops, but this trial aims to prevent it from developing in the first place by treating the infection early.
If your baby is enrolled, you will give the medication by mixing it into food or milk for 2–3 days starting when your baby presents to the hospital or emergency department with a respiratory infection. Your baby may have nasal swabs taken at the time of enrollment and again at day 7 to help researchers understand what's happening in the airways. The study involves a small number of babies and is designed to gather early safety and effectiveness information.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Enrollment target
~60 participants
Started
October 2026
Primary completion
December 2027
Age range
4 Months – 24 Months
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Caroline Merck, MPH
Ann & Robert H Lurie Children's Hospital of Chicago
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.